Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D05KBP
|
||||
Former ID |
DIB001403
|
||||
Drug Name |
INO-8875
|
||||
Synonyms |
PJ-875; Adenosine A1 agonist (atrial fibrillation), Inotek; Adenosine A1 agonist (glaucoma), Inotek
|
||||
Indication | Glaucoma [ICD9: 365; ICD10:H40-H42] | Phase 1/2 | [1] | ||
Company |
Inotek pharmaceuticals
|
||||
Structure |
![]() |
Download2D MOL |
|||
Canonical SMILES |
C1CCCC1Nc1ncnc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO[N+](=O<br />)[O-])O3)cnc12
|
||||
Target and Pathway | |||||
Target(s) | Adenosine A1 receptor | Target Info | Agonist | [2] | |
KEGG Pathway | cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | |||||
Sphingolipid signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
RANKL Signaling Pathway | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Reactome | Adenosine P1 receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Nucleotide GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT01123785) A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in AdultsWith Ocular Hypertension or Primary Open-Angle Glaucoma. U.S. National Institutes of Health. | ||||
REF 2 | INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. J Pharmacol Exp Ther. 2013 Jan;344(1):59-67. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.